
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dafsolimab Setaritox,Grisnilimab Setaritox
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Philikos Begins Phase 1/2 Study of T-Guard® in Patients with Systemic Sclerosis
Details : T-Guard is designed to rapidly and safely reset the body’s immune system in life-threatening T-cell mediated conditions such as severe autoimmune diseases.
Product Name : T-Guard
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 20, 2025
Lead Product(s) : Dafsolimab Setaritox,Grisnilimab Setaritox
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
